TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Center Study of New Medications to Treat Vaginal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:~* Capable of providing written informed consent or assent~* Currently not menstruating and not anticipating menses during treatment~* If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control~* Negative pregnancy test~* Other criteria as identified in the protocol~Exclusion Criteria:~* Other infectious causes of vulvovaginitis~* Subject has recently used, or is expected to require the concomitant use of prohibited medications/products~* Nursing mother~* Use of any investigational drug within 30 days of enrollment~* History of hypersensitivity to any ingredient/component of the formulations~* Other criteria as identified in the protocol

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metronidazole vaginal gel (Type: ACTIVE_COMPARATOR): One applicator full at bedtime
- Gel vehicle (Type: PLACEBO_COMPARATOR): One applicator full at bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of epilepsy with PGTC or SGTC seizures based on focal or idiopathic generalized epilepsy~2. Active epilepsy with GTC seizures, demonstrated by the occurrence of at least 1 GTC seizure within 3 months before inclusion~3. The decision to prescribe perampanel was made by the physician before and irrespective of his/her decision to include the participant in the study~4. Receiving treatment with perampanel in line with the current Fycompa (perampanel) SmPC~5. Perampanel must either be newly administered as the only add-on treatment to a current antiepileptic drug (AED) monotherapy or must be planned to substitute one of two AEDs of a current dual therapy planned to be stopped within 2 months after initiation of treatment with perampanel. It will be specified which AED is planned to be substituted by perampanel upon inclusion. It is assumed that participants start treatment with perampanel closely after the baseline visit. Retrospective inclusions will be allowed, but only if the time between the initiation of perampanel treatment and inclusion does not exceed 7 calendar days. In this case, the baseline visit documentation should reflect the situation (including seizure situation 3 months before baseline and baseline medication) to the date perampanel treatment was initiated~Exclusion Criteria:~1. Participants with known psychogenic non-epileptic seizures~2. The participant had already received perampanel in the past~3. Simultaneous participation in an interventional clinical study and/or taking an investigational drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perampanel (Type: None): Participants with PGTC or SGTC seizures may receive perampanel tablets or oral suspension as only add-on therapy based on physicians decision in accordance with summary of product characteristics (SmPC) and will be observed at baseline, 6 months (intermediate visit), and 12 months (final visit).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nitric Oxide in Cardiopulmonary Bypass for Renal Protection in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Age above 18 years; planned primary cardiac intervention with cardiopulmonary bypass including coronary artery bypass grafting, valve surgery, and surgical reconstructions of the left ventricle.~Exclusion Criteria:~Preoperative anemia; the intake of nephrotoxic drugs or the use of X-ray contrast within 72 h before surgery; active phase of endocarditis; emergency surgery; chronic kidney disease; hematologic diseases accompanied by hemolysis; complications of the surgery and the early postoperative period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitric Oxide (Type: EXPERIMENTAL): Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
- Standard CPB (Type: PLACEBO_COMPARATOR): Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit (Standard CPB) during cardiac surgery. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to participation in the study.~* Treatment-naïve choroidal neovascularization (CNV) secondary to AMD.~* BCVA ETDRS score between 83 and 25 letters, inclusive, in the Study Eye.~* Decrease in vision in the Study Eye determined by the Investigator to be primarily the result of wAMD.~* Other protocol-specified inclusion criteria may apply~Exclusion Criteria:~* BCVA of hand motion or worse in the non-Study Eye or non-physical presence of a non-Study Eye (i.e., monocular).~* Active or suspected ocular or periocular infection or inflammation.~* CNV secondary to other causes in the Study Eye.~* Any history or evidence of a concurrent ocular condition present in the Study Eye, that in the opinion of the Investigator could require either medical or surgical intervention or affect macular edema or alter visual acuity during the study.~* Uncontrolled glaucoma in the Study Eye.~* Significant media opacities, including cataract, in the Study Eye that might interfere with visual acuity, assessment of safety, OCT or fundus photography.~* Cataract in the Study Eye that in the judgment of the Investigator is expected to require surgical extraction within 12 months of screening.~* Women who are pregnant or lactating or intending to become pregnant during the study.~* Recent history (within the 6 months prior to screening) of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure or any acute coronary event.~* History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product.~* Uncontrolled blood pressure defined as a systolic value ≥180 mmHg or diastolic value ≥100 mmHg while at rest.~* Other protocol-specified exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KSI-301 (Treatment Group A) (Type: EXPERIMENTAL): Intravitreal injection of KSI-301 (5 mg) at Day 1 once every 4 weeks via intravitreal injection through Week 44.
- Aflibercept (Treatment Group B) (Type: ACTIVE_COMPARATOR): Intravitreal injection of aflibercept (2 mg) once every 4 weeks for 3 monthly doses followed by intravitreal injection of aflibercept (2 mg) once every 8 weeks from Week 16 to Week 44. Sham injections will be administered at each monthly visit where an active treatment is not administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas;cancer which is unresectable, locally advanced or metastatic.~Must have evidence of disease (clinical or radiological). Male or female, 18 years or older. Patients may have received prior radiation treatment for management of local disease providing that disease progression has been documented.~All toxicities have resolved, and the last fraction of radiation treatment was completed at least 4 weeks prior to randomization.~Patients may not have received prior chemotherapy, other then 5FU (+/- folic acid) or gemcitabine given concurrently with radiation treatment as a 'radiosensitiser.'

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic obstructive pulmonary disease~* acute respiratory failure under ventilator support for less than 72 hours~* endotracheal tube inserted~Exclusion Criteria:~* confirmed asthma~* Acute Physiology and Chronic Health Evaluation II score over 35~* a co-morbidity of septic shock

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Individualized dosing (Type: EXPERIMENTAL): * Ventilator support~* Determining personal target airway resistance~* Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~* Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~* Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~* Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)
- Fixed dosing (Type: ACTIVE_COMPARATOR): * Ventilator support~* Determining personal target airway resistance~* Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~* Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~* Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~* No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Surgical Techniques to Achieve Patella Symmetry During Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for primary total knee arthroplasty with planned patellar resection by one of the three staff surgeons included in the study.~* Patient must be able and willing to provide consent for study participation~Exclusion Criteria:~* Patient in need of revision total knee arthroplasty or having already undergone prior total knee arthroplasty~* Patient not in need of patellar resection during their primary total knee arthroplasty~* Unwilling or unable to provide consent for participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Cutting Guide Technique (Type: ACTIVE_COMPARATOR): The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
- Haptic Feedback Technique (Type: ACTIVE_COMPARATOR): It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
- Four Quadrant Technique (Type: ACTIVE_COMPARATOR): Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with known coronary artery disease (defined as prior type I myocardial infarction, coronary revascularization, percutaneous or surgical, or presence of at least a 50% stenosis in any major epicardial vessel).~* Age \> 18 years old~* On aspirin 81mg/qd for at least 1 month~Exclusion criteria:~* Inability to provide written informed consent~* Hemodynamic instability~* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 30 days~* Known allergies to ticagrelor or cangrelor~* Considered at high risk for bleeding~* History of intracranial bleeding/hemorrhagic stroke~* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxoban) within past 30 days~* Known platelet count \<80x106/mL~* Known hemoglobin \<10 g/dL~* Active bleeding~* Known end stage renal disease on hemodialysis~* Known severe hepatic dysfunction~* Acute or severe bronchial asthma or upper airway obstruction.~* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.~* Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~* Pregnant females \[women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion
- Placebo (Type: PLACEBO_COMPARATOR): Ticagrelor loading dose followed after 1 hour by placebo infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin in the Prevention of Acute Mountain Sickness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults~Exclusion Criteria:~* History of serious illness~* Current smoker or Hemoglobin \>15.5gm/dL~* Uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Erythropoietin (Type: EXPERIMENTAL): Erythropoietin 10,000U, weekly, for 4 weeks Last dose: 1 week before departure (10days before high altitude)
- Control (Type: NO_INTERVENTION): No erythropoietin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Able to be dosed in both eyes, able and willing to make the required study visits and to follow instructions.~* Negative urine pregnancy test if female of childbearing potential and use adequate birth control throughout the study period.~* Diagnostic skin test indicative of allergy for cat hair, cat dander, grasses, ragweed, dust mite, dog dander, cockroach and/or trees within 24 months prior to Visit 1 or at Visit 1.~* History of seasonal or perennial allergic conjunctivitis for at least 1 year prior to Visit 1.~* Best-corrected visual acuity of 55 or greater in each eye as measured by ETDRS (letters read method).~* Manifest a positive bilateral Conjunctival Allergen Challenge (CAC) test response.~* Willing to discontinue contact lens wear for at least 72 hours prior to Visit 1 and throughout the study.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Known history or presence of persistent dry eye syndrome, or currently requires frequent use of artificial tears, gels or lubricants, presence of punctal plugs, use of Restasis®, or topical ocular corticosteroids for dryness of eyes.~* Presence of an ocular condition that may affect the study outcomes.~* History or evidence of ocular surgery (including refractive procedures such as LASIK, PRK and RK) within 6 months of Visit 1.~* Presence of signs/symptoms of active allergic conjunctivitis at the start of Visits 1, 2, 3A, or 4.~* History of anaphylactic reaction to any allergens used in this study.~* Current evidence or recent (within 6 months) history of severe, unstable, or uncontrolled medical conditions and/or other relevant systemic diseases.~* Use of any disallowed medication without protocol-specified washout period prior to Visit 1, or during the study.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AL-4943A (Type: EXPERIMENTAL): AL-4943A ophthalmic solution, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
- PATADAY (Type: ACTIVE_COMPARATOR): Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
- PATANOL (Type: ACTIVE_COMPARATOR): Olopatadine hydrochloride ophthalmic solution, 0.1%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
- Vehicle (Type: PLACEBO_COMPARATOR): AL-4943A ophthalmic solution vehicle, 1 drop per eye Day 0, followed by 1 drop per eye Day 14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and non-pregnant women between the ages of 18 and 55~* Confirmed diagnosis of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)~* Baseline ADHD score of at least 24~Exclusion Criteria:~* Weight less than 100 pounds or greater than 250 pounds~* Psychiatric diagnosis such as a severe comorbid Axis II or Axis I disorder~* Pregnancy or breastfeeding~* History of seizures~* Positive urine drug screen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SPD465 (50 or 75 mg) (Type: EXPERIMENTAL): None
- Immediate Release Amphetamine salt (25 mg) (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amphotericin B Treatment in Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Parasitologically proved kala-azar~Exclusion Criteria:~* HIV positive serology

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete